

Altasciences is bringing their 25+ years of preclinical, clinical, bioanalytical and manufacturing experience to bear in the fight against COVID-19.

- Comprehensive safety assessment services in rodent and non-rodent species, with 140 custom-designed animal rooms, including European housing
- Clinical pharmacology services offered in both the U.S. and Canada, with 400 beds and decades of experience
- Expertise in large and small molecules
- Bioanalytical experience, with a rich history in potential COVID-19 treatments and validated assays
- Contract manufacturing and analytical services including phase I through commercial manufacturing

Below is a list of the validated assays available, for analytes that have been identified as possible therapeutics for COVID-19.

VALIDATED ASSAYS

ANALYTE	Abacavir
Analytical Range	25 ng/mL to 10,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	10,817
Reference	The Drugs That Could Cure Coronavirus—and the Companies That Make Them

ANALYTE	Atazanavir
Analytical Range	10 ng/mL to 8,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	1755
References	Potential Treatments for COVID-19; a Narrative Literature Review Discovering drugs to treat coronavirus disease 2019 (COVID-19)

ANALYTE	Azithromycin
Analytical Range	5 ng/mL to 3,000 ng/mL 2 ng/mL to 900 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	14,100
Reference	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

VALIDATED ASSAYS

ANALYTE	Colchicine
Analytical Range	20 pg/mL to 18,000 pg/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	6,913
References	Colchicine COVID-19 Trial Underway Canadian researchers study whether a cheap gout drug can slash COVID-19 deaths

ANALYTE	Darunavir
Analytical Range	50 ng/mL to 20,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	7,713
Reference	Coronavirus puts drug repurposing on the fast track

ANALYTE	Emtricitabine
Analytical Range	10 ng/mL to 4,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	24,315
References	Coronavirus puts drug repurposing on the fast track COVID-19 Registered Trials - and analysis

ANALYTE	Imatinib	N-desmethylimatinib
Analytical Range	10 ng/mL to 4,000 ng/mL	5 ng/mL to 400 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA	
Number of samples analyzed to date	13,619	
Reference	Discovering drugs to treat coronavirus disease 2019 (COVID-19)	

ANALYTE	Ivermectin B1a	Ivermectin B1b
Analytical Range	0.25 ng/mL to 75 ng/mL	25 pg/mL to 7,500 pg/mL
Matrix/Anticoagulant	Human plasma/EDTA	
Number of samples analyzed to date	4,021	
References	Anti-Parasite Drug Ivermectin Stunts COVID-19 Virus Culture in Lab Study The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Ivermectin shows activity against COVID-19 in cell cultures	

ANALYTE	Lamivudine
Analytical Range	10 ng/mL to 5,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	11,101
Reference	Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

VALIDATED ASSAYS

ANALYTE	Montelukast
Analytical Range	2.5 ng/mL to 750 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	20,719
Reference	Discovering drugs to treat coronavirus disease 2019 (COVID-19)

ANALYTE	Moxifloxacin
Analytical Range	10 ng/mL to 4,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	10,219
Reference	Potential Treatments for COVID-19; a Narrative Literature Review

ANALYTE	Oseltamivir	Oseltamivir carboxylate
Analytical Range	0.5 ng/mL to 200 ng/mL	2.5 ng/mL to 1,000 ng/mL
Matrix/Anticoagulant	Human plasma/NaFKO	
Number of samples analyzed to date	7,076	
Reference	Coronavirus puts drug repurposing on the fast track	

ANALYTE	Ribavirin
Analytical Range	5 ng/mL to 2,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	830
References	Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs Discovering drugs to treat coronavirus disease 2019 (COVID-19) Coronavirus puts drug repurposing on the fast track

ANALYTE	Ritonavir
Analytical Range	10 ng/mL to 5,000 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	4,174
References	Coronavirus puts drug repurposing on the fast track We'll soon know if covid-19 can be treated with HIV and Ebola drugs Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

ANALYTE	Tenofovir
Analytical Range	2.5 ng/mL to 800 ng/mL
Matrix/Anticoagulant	Human plasma/EDTA
Number of samples analyzed to date	27,490
References	Coronavirus puts drug repurposing on the fast track COVID-19 trials registered up to 8 March 2020—an analysis of 382 studies